Folotyn for Non-Hodgkin's Lymphoma Baltimore MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Maria Jacobs
(410) 332-9055
227 Saint Paul Pl
Baltimore, MD
Specialty
Radiation Oncology

Data Provided by:
Sadaf Taimur, MD
(410) 328-7157
22 S Greene St
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
William Frank Regine, MD
(410) 328-2326
22 S Greene St Rm GGK0101
Baltimore, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Languages
Spanish
Education
Medical School: Suny-Hlth Sci Ctr At Syracuse, Coll Of Med, Syracuse Ny 13210
Graduation Year: 1987

Data Provided by:
Ronald Benjamin Gartenhaus
(410) 328-5793
22 S Greene St
Baltimore, MD
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Ashraf Z Badros, MD
22 S Greene St
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Ain Shams Univ, Fac Of Med, Abbasia, Cairo, Egypt (330-04 Pr 1/71)
Graduation Year: 1985

Data Provided by:
Armando Sardi
(410) 332-9294
227 Saint Paul Pl
Baltimore, MD
Specialty
General Surgery, Surgical Oncology

Data Provided by:
King F Kwon, MD
(410) 328-6366
22 S Greene St Rm N4E35
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Gorgun Akpek, MD
(410) 328-1230
22 S Greene St Rm N9E12
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Hacettepe Univ, Tip Fak, Hacettepe, Ankara, Turkey
Graduation Year: 1985

Data Provided by:
Dwight Daehoon Im, MD
(410) 332-9200
301 Saint Paul St
Baltimore, MD
Specialties
Oncology (Cancer), Gynecological Oncology
Gender
Male
Education
Medical School: Umdnj-Robt W Johnson Med Sch, New Brunswick Nj 08901
Graduation Year: 1989

Data Provided by:
Suman Ra, MD
(410) 554-6653
3333 N Calvert St Ste 107
Baltimore, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com